Spotlight On... BioClinica rolls out tech-enabled postapproval research service; Illumina adds software in acquisition; Ono picks Medidata for immuno-oncology trials; and more...

BioClinica has added a postapproval research unit to its service offerings. The division, which the company has set up to meet rising demand for postapproval research, will make use of BioClinica's technology capabilities. Specifically, BioClinica has applied its skills to the creation of a postapproval technology platform, which is designed to simplify the research process while providing access to study metrics. Release

> Illumina ($ILMN) added software capabilities through the acquisition of Conexio Genomics. Release

> Ono Pharmaceutical picked Medidata ($MDSO) to support its immuno-oncology clinical trials. News

> Authorea raised $1.5 million to advance its platform to support the collaborative writing, sharing and discussion of research. More

> PerkinElmer ($PKI) teamed up with Attivio to introduce a data platform. Item

> Auria Biobank and BC Platforms partnered to develop a genomic data management system. Post

> Glencoe Software landed a deal to provide technology to the National Phenotypic Screening Centre. News

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.